MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Medical Treatment Termination in Parkinson’s Disease Patients after Hepad Therapy: A Case Series

D.H. Kim, D.H. Kim, J.J. Choi, B.J. Park (Daejeon, Republic of Korea)

Meeting: 2017 International Congress

Abstract Number: 1443

Keywords: Pharmacotherapy

Session Information

Date: Thursday, June 8, 2017

Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment

Session Time: 1:15pm-2:45pm

Location: Exhibit Hall C

Objective:

To report seven clinical cases of treatment completion and improvement of symptoms after a PD therapy regimen that included Hepad.

Background:

DOPA decarboxylase inhibitor and dopamine supplements are widely prescribed to patients with Parkinson’s disease (PD). However, these drugs simply relieve PD symptoms temporarily, and may be associated with severe side effects such as dyskinesia. Moreover, they cannot cure or arrest the progress of PD. HEaling herbmedicine of PArkinson’s Disease (Hepad) is a herbal medicine with a formulation based on Korean medicinal theory, and has been prescribed to PD patients in Korean medical clinics.

Methods:

Hepad was prescribed to seven patients who were diagnosed with PD. Conventional PD medical treatment was accompanied by Hepad therapy in five patients; the other two were treated with Hepad only. Hepad was administered one to three times per day, and the daily dose was reduced gradually.

Results:

Four of the five patients who received Hepad as an adjunct to conventional PD medicine discontinued medical treatment because of an improvement in PD symptoms within three to nine months, which was followed by Hepad-only therapy for two to fourteen months. The remaining patient stopped receiving conventional treatment and is taking Hepad only, and is experiencing ameliorated symptoms. Therapy was terminated in Hepad-only treated patients because of decreased symptoms of tremor and malaise.

Conclusions:  

The clinical cases in this study suggest that Hepad, which is based on Korean medicinal theory, is effective in PD patients either exclusively or as an adjunct to conventional PD medicines. Hepad treatment may resolve some of the limitations of conventional PD treatment and offer novel therapeutic opportunities in PD.  

To cite this abstract in AMA style:

D.H. Kim, D.H. Kim, J.J. Choi, B.J. Park. Medical Treatment Termination in Parkinson’s Disease Patients after Hepad Therapy: A Case Series [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/medical-treatment-termination-in-parkinsons-disease-patients-after-hepad-therapy-a-case-series/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/medical-treatment-termination-in-parkinsons-disease-patients-after-hepad-therapy-a-case-series/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley